0001193125-20-264855.txt : 20201006 0001193125-20-264855.hdr.sgml : 20201006 20201006172603 ACCESSION NUMBER: 0001193125-20-264855 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20201006 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20201006 DATE AS OF CHANGE: 20201006 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CATALYST PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001369568 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33057 FILM NUMBER: 201227596 BUSINESS ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 1250 CITY: CORAL GABLES STATE: FL ZIP: 33134 BUSINESS PHONE: (305) 529-2522 MAIL ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 1250 CITY: CORAL GABLES STATE: FL ZIP: 33134 FORMER COMPANY: FORMER CONFORMED NAME: CATALYST PHARMACEUTICAL PARTNERS, INC. DATE OF NAME CHANGE: 20110215 FORMER COMPANY: FORMER CONFORMED NAME: Catalyst Pharmaceutical Partners, Inc. DATE OF NAME CHANGE: 20060719 8-K 1 d32692d8k.htm FORM 8-K Form 8-K
false 0001369568 0001369568 2020-10-06 2020-10-06

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): October 6, 2020

 

 

CATALYST PHARMACEUTICALS, INC.

(Exact Name Of Registrant As Specified In Its Charter)

 

 

 

Delaware   001-33057   76-0837053

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

355 Alhambra Circle

Suite 1250

Coral Gables, Florida

  33134
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (305) 420-3200

Not Applicable

Former Name or Former address, if changed since last report

 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

 

Name of Exchange

on Which Registered

 

Ticker

Symbol

Common Stock, par value $0.001 per share   NASDAQ Capital Market   CPRX

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 


Item 8.01

Other Events

On October 6, 2020, the Company issued a press release announcing that the United States Patent and Trademark Office (USPTO) has issued a new U.S. patent to the Company for Firdapse®, U.S. Patent No. 10,793,893. The patent, “Methods of Administering 3,4-Diaminopyridine”, claims methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject’s acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases. The patent will expire on April 7, 2034.

The Company had previously announced the USPTO’s issuance of a Notice of Allowance for this patent on August 11, 2020. The patent is available on the USPTO’s public website.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01

Financial Statements and Exhibits.

 

  (d)

Exhibits

 

99.1    Press release issued by the Company on October 6, 2020.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

2


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Catalyst Pharmaceuticals, Inc.
By:  

/s/ Alicia Grande

  Alicia Grande
  Vice President, Treasurer and CFO

Dated: October 6, 2020

 

3

EX-99.1 2 d32692dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Catalyst Pharmaceuticals Announces Issuance of U.S. Patent for Firdapse®

- Issued Patent is the First Covering Firdapse®

CORAL GABLES, Fla., October 06, 2020 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued a new U.S. patent to Catalyst Pharmaceuticals for Firdapse® (amifampridine), U.S. Patent No. 10,793,893, Methods of Administering 3,4-Diaminopyridine, expiring April 7, 2034.

“We are pleased that our patent for Firdapse® (amifampridine) has issued and believe that it will create significant barriers to therapeutically equivalent generic competition from entering the market for approximately nine years beyond orphan drug exclusivity,” said Patrick J. McEnany, Chairman and Chief Executive Officer of Catalyst. Mr. McEnany added, “We remain committed to serving the neuromuscular community by continuing to investigate Firdapse® for other rare neurodegenerative diseases. We also look forward to results from various investigator-sponsored trials that, if positive, will strengthen the value proposition for the use of Firdapse®.”

“This patent is directed to innovative methods of administering amifampridine to slow metabolizers of amifampridine,” commented Steven Miller, Ph.D., Chief Operating Officer and Chief Scientific Officer of Catalyst. Dr. Miller added, “Within the next few days, we intend to submit a request to the FDA that this patent be listed in Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the FDA’s Orange Book), which is published by the United States Food and Drug Administration.”

Amifampridine is extensively metabolized by N-Acetyl Transferase, type 2 (or NAT2) and the rate of this metabolism can be quite variable in patients. The patent is directed to the use of suitable doses of amifampridine to treat patients, regardless of the therapeutic indication, that are slow metabolizers of amifampridine. Any drug product containing amifampridine with a label that states the patented dosing regimens and doses in the Dosing and Administration section prior to 4/7/2034 could possibly infringe this patent. Generic drug product labels would necessarily have to do this, and Catalyst would take appropriate action to protect its intellectual property.

About Firdapse®

Firdapse® (amifampridine) 10 mg tablets is an oral, nonspecific, voltage-dependent, potassium (K+) channel blocker that causes depolarization of the presynaptic membrane and slows or inhibits repolarization. This action results in the opening of slow voltage-dependent calcium (Ca2+) channels, allowing for a subsequent influx of Ca2+. In turn, it induces the exocytosis of synaptic vesicles containing Acetylcholine (ACh) to release more ACh into the synaptic cleft, enhancing neuromuscular transmission, and providing for improved muscle function.


About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), anti-MuSK antibody positive myasthenia gravis (MuSK-MG) and spinal muscular atrophy (SMA) Type 3. Catalyst’s new drug application for Firdapse® (amifampridine) 10 mg tablets for the treatment of adults with LEMS was approved in November 2018 by the U.S. Food & Drug Administration (“FDA”), and Firdapse is now commercially available in the United States. Further, Canada’s national healthcare regulatory agency, Health Canada, recently approved the use of Firdapse® (amifampridine) for the treatment of patients in Canada with LEMS.

Firdapse is currently being evaluated in clinical trials for the treatment of MuSK-MG and SMA Type 3 and has received Orphan Drug Designation from the FDA for myasthenia gravis.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst’s actual results in future periods to differ materially from forecasted results. A number of factors, including (i) the scope of protection from competition provided by the patent, and (ii) those factors described in Catalyst’s Annual Report on Form 10-K for fiscal year 2019 and its other filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect Catalyst. Copies of Catalyst’s filings with the SEC are available from the SEC, may be found on Catalyst’s website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

 

Investor Contact

Brian Korb

Solebury Trout

(646) 378-2923

bkorb@troutgroup.com

  

Company Contact

Patrick J. McEnany

Catalyst Pharmaceuticals

Chief Executive Officer

(305) 420-3200

pmcenany@catalystpharma.com

Media Contact

David Schull

Russo Partners

(212) 845-4271

david.schull@russopartnersllc.com

###

 

2

EX-101.SCH 3 cprx-20201006.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 cprx-20201006_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, Address Line Three Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Security 12b Title Security 12b Title Security Exchange Name Security Exchange Name Trading Symbol Trading Symbol Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 cprx-20201006_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g32692g1007014232367.jpg GRAPHIC begin 644 g32692g1007014232367.jpg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end XML 7 d32692d8k_htm.xml IDEA: XBRL DOCUMENT 0001369568 2020-10-06 2020-10-06 false 0001369568 8-K 2020-10-06 CATALYST PHARMACEUTICALS, INC. DE 001-33057 76-0837053 355 Alhambra Circle Suite 1250 Coral Gables FL 33134 (305) 420-3200 Common Stock, par value $0.001 per share NASDAQ CPRX false false false false false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Document and Entity Information
Oct. 06, 2020
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001369568
Document Type 8-K
Document Period End Date Oct. 06, 2020
Entity Registrant Name CATALYST PHARMACEUTICALS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-33057
Entity Tax Identification Number 76-0837053
Entity Address, Address Line One 355 Alhambra
Entity Address, Address Line Two Circle
Entity Address, Address Line Three Suite 1250
Entity Address, City or Town Coral Gables
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33134
City Area Code (305)
Local Phone Number 420-3200
Security 12b Title Common Stock, par value $0.001 per share
Security Exchange Name NASDAQ
Trading Symbol CPRX
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.catalystpharma.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d32692d8k.htm cprx-20201006.xsd cprx-20201006_lab.xml cprx-20201006_pre.xml d32692dex991.htm http://xbrl.sec.gov/dei/2019-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d32692d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d32692d8k.htm" ] }, "labelLink": { "local": [ "cprx-20201006_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "cprx-20201006_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "cprx-20201006.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "cprx", "nsuri": "http://www.catalystpharma.com/20201006", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d32692d8k.htm", "contextRef": "duration_2020-10-06_to_2020-10-06", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.catalystpharma.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d32692d8k.htm", "contextRef": "duration_2020-10-06_to_2020-10-06", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.catalystpharma.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.catalystpharma.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.catalystpharma.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.catalystpharma.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.catalystpharma.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.catalystpharma.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three", "terseLabel": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.catalystpharma.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.catalystpharma.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.catalystpharma.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.catalystpharma.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.catalystpharma.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.catalystpharma.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.catalystpharma.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.catalystpharma.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.catalystpharma.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.catalystpharma.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.catalystpharma.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.catalystpharma.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.catalystpharma.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.catalystpharma.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.catalystpharma.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.catalystpharma.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.catalystpharma.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.catalystpharma.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001193125-20-264855-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-20-264855-xbrl.zip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end